 |
Video: What is a Stock Split?
|
 |
| Co-Diagnostics, Inc. is a molecular diagnostics company, which develops, manufactures and markets diagnostics technologies. Co.'s technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). Co. also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious disease. Its diagnostics systems enable dependable, low-cost, molecular testing for organisms and genetic diseases by automating or simplifying historically complex procedures in both the development and administration of tests. According to our CODX split history records, Co-Diagnostics has had 1 split. | |
 |

Co-Diagnostics (CODX) has 1 split in our CODX split history database. The split for CODX took place on January 02, 2026. This was a 1 for 30 reverse split, meaning for each 30 shares of CODX owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 33.3333333333333 share position following the split.
When a company such as Co-Diagnostics conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.
Looking at the CODX split history from start to finish, an original position size of 1000 shares would have turned into 33.3333333333333 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Co-Diagnostics shares, starting with a $10,000 purchase of CODX, presented on a split-history-adjusted basis factoring in the complete CODX split history.

Growth of $10,000.00
Without Dividends Reinvested
|
| Start date: |
07/13/2017 |
|
| End date: |
05/08/2026 |
|
| Start price/share: |
$168.00 |
|
| End price/share: |
$2.53 |
|
| Dividends collected/share: |
$0.00 |
|
| Total return: |
-98.49% |
|
| Average Annual Total Return: |
-37.84% |
|
| Starting investment: |
$10,000.00 |
|
| Ending investment: |
$150.59 |
|
| Years: |
8.82 |
|
|
 |
| Date |
Ratio |
| 01/02/2026 | 1 for 30 |
|
 |